In addition, selective modulators of ERβ were effective in protecting against AD pathology in transgenic models of the disease [43], and treatment with hydroxytyrosol acetate caused ERβ-dependent cognitive improvement in APP/PS1 transgenic mice [44]. This evidence concerns the gene APP and Alzheimer disease.